Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: xcr600 who wrote (11775)	4/25/2003 10:07:01 AM
From: RockyBalboa	Respond to of 48461

ENMD a bit bouncy today, little sucker, DKEY sure a bummer, but so it goes with small stocks after earnings...

To: xcr600 who wrote (11775)	4/25/2003 11:08:05 AM
From: RockyBalboa	Respond to of 48461

Ugh, looks like small caps get a general margin call today, big losers today.,.. RSTN mauled on sec investigation news..., perhaps the sec should be halted - they put existing investor money at risk with their sudden announcements. On the other hand they create buying opportunities (sometimes).

To: xcr600 who wrote (11775)	5/7/2003 8:39:30 AM
From: RockyBalboa	Respond to of 48461

CombiMatrix Synthesizes Potential SARS Drugs Wednesday May 7, 7:32 am ET Press Release Source: Acacia Research Corporation NEWPORT BEACH, Calif.--(BUSINESS WIRE)--May 7, 2003-- Molecules of SARS specific siRNA will be evaluated as drugs against SARS by the National Institute of Allergy and Infectious Diseases (NIAID) and the US Army Medical Research Institute of ADVERTISEMENT Infectious Diseases (USAMRIID) Acacia Research Corporation (Nasdaq:ACTG - News; Nasdaq:CBMX - News) announced today that CombiMatrix has produced pools of small interfering RNA molecules directed at specific genes of the SARS corona virus. CombiMatrix is collaborating with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the Nation Institutes of Health (NIH) and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) to conduct the initial screening of the siRNA samples against the SARS corona virus. Small interfering RNA (siRNA) molecules are being evaluated by many researchers and pharmaceutical companies as therapeutics and are also being used to elucidate important biochemical pathways. The rapid design and preparation of siRNA molecules, by CombiMatrix, enables high throughput screening of such molecules as therapeutics against diseases. CombiMatrix's microarray platform technology enabled the rapid preparation of customized siRNA molecules based on the published sequence of the SARS virus. CombiMatrix scientists targeted two genes of the virus believed to be regulators of viral replication. One was a RNA-dependent RNA polymerase, the other was an NTPase/helicase domain. Molecular design, by CombiMatrix scientists, involved identifying potential therapeutic sequences and eliminating those with significant homology to the human genome and other interfering sequences. The result was approximately 60 potential drugs, which were synthesized, along with appropriate controls, PCR probes and linkers for transcription, on a CombiMatrix microarray. These sequences were synthesized overnight after molecular design. The molecules were then amplified and transcribed for use in drug screening experiments. The whole process took less than one week. "Our recent accomplishments demonstrate the ability of our technology to rapidly prepare genetic content on a microarrray. Previously, on April 15 CombiMatrix prepared the first SARS genetic microarray within 48 hours after the publication of the virus genome. In addition to proving that our products are useful in many areas including drug-target identification and validation, this demonstration illustrates the capabilities of our technology to actually design and synthesize potential drugs," said Dr. Amit Kumar, President and CEO of CombiMatrix Corporation. "We are excited about these capabilities and as such have filed patents on the specific molecules which could become drugs against SARS. While SARS is the first test case of our platform technology, this approach is applicable to many diseases including those associated with other infectious agents." CombiMatrix plans to offer these drug candidates to partners to complete the pre-clinical and clinical development if these molecules and others, which CombiMatrix develops using its platform technology, show efficacy in initial tests. CombiMatrix is focused on executing its strategy of utilizing corporate relationships to fund the development of its platform technology and associated products in all areas including potential therapeutics. ABOUT ACACIA RESEARCH CORPORATION Acacia Research Corporation comprises two operating groups, Acacia Technologies Group and CombiMatrix Group. The Acacia Technologies group licenses its DMT and V-Chip technologies to media and electronics companies. The DMT technology covers the transmission and receipt of digital audio and digital video content, commonly known as audio on-demand, video on-demand, and audio/video streaming, and is supported by 5 U.S. and 17 international patents. The CombiMatrix group is developing a platform technology to rapidly produce customizable active biochips, which are semiconductor-based tools for use in identifying and determining the roles of genes, gene mutations and proteins. CombiMatrix's technology has a wide range of applications, from DNA synthesis/diagnostics to immunochemical detection. Information about Acacia Research Corporation and the Acacia Technologies group is available at www.acaciaresearch.com. Information about the CombiMatrix group is available at www.combimatrix.com. Acacia Research-Acacia Technologies (Nasdaq:ACTG - News) and Acacia Research-CombiMatrix (Nasdaq:CBMX - News) are both classes of common stock issued by Acacia Research Corporation and are intended to reflect the performance of the respective operating groups and are not issued by the operating groups. Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the recent economic slowdown affecting technology companies, our ability to successfully develop products, rapid technological change in our markets, changes in demand for our future products, legislative, regulatory and competitive developments and general economic conditions. Our Annual Report on Form 10-K, recent and forthcoming Quarterly Reports on Form 10-Q, recent Current Reports on Forms 8-K and 8-K/A, and other SEC filings discuss some of the important risk factors that may affect our business, results of operations and financial condition. We undertake no obligation to revise or update publicly any forward-looking statements for any reason. -------------------------------------------------------------------------------- Contact: Acacia Research Corporation Bret L. Undem (Media Relations) 425/493-2293 Fax: 425/493-2010